O uso do sistema intrauterino liberador de 52mg de levonorgestrel no Sistema Único de Saúde (SUS) do Brasil: uma revisão sistemática
Data
2023-06-23
Autores
Pereira, Victoria Santos Delicio 
Orientadores
Fonseca, Fernando Luiz Affonso
Tipo
Trabalho de conclusão de curso
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Introdução: Uma pesquisa realizada em 2021 revelou que 62% das mulheres brasileiras já
tiveram pelo menos uma gravidez não intencional. Esse índice é considerado alarmante, uma
vez que está 14% acima da média mundial e mais alto do que a média nacional em 2012, que
era de 55%. Pode-se considerar que, a falta de conhecimento e acesso aos métodos
contraceptivos é a principal causa desse problema. Para reduzir esses números, é necessário
ampliar a divulgação de informações sobre contracepção no SUS, garantir acesso a métodos
modernos e capacitar as equipes multiprofissionais para o aconselhamento contraceptivo das
pacientes. É também importante incentivar e capacitar esses profissionais e valorizar a
participação dos farmacêuticos no processo. O presente trabalho enfatiza o uso do sistema
intrauterino liberador de 52mg de levonorgestrel (Mirena®), como uma alternativa moderna,
segura e eficaz para contracepção. A ampliação do acesso a métodos contraceptivos modernos,
como o Mirena®, pode contribuir significativamente para a redução dos índices de gravidez
inesperada no Brasil.
Objetivo: Avaliar os benefícios do uso do Sistema Intrauterino liberador de 52mg de
levonorgestrel no Sistema Único de Saúde (SUS) do Brasil.
Métodos: trata-se de uma revisão sistemática de estudos selecionados referentes ao uso do
Mirena® no Brasil. Foi realizada uma busca em bases de dados como SciELO e Pubmed,
empregando a combinação das palavras-chaves: sistema intrauterino de levonorgestrel e Brasil,
nos idiomas inglês e português. Foram encontradas e analisadas cinco publicações consideradas
relevantes.
Resultados e Discussões: As publicações analisadas reforçam a ideia de que, o Mirena® é
muito eficaz, tanto para o controle das taxas de gestação não planejada, quanto para o
tratamento de SUA (Sangramento Uterino Anormal) idiopático e proteção endometrial. Além
disso, possui algumas vantagens quando comparado a outros tratamentos e métodos, e seu
custo-benefício pode ser vantajoso. Por outro lado, é necessário que, em paralelo, haja
fortalecimento do sistema público de saúde e investimento em pesquisas acerca do assunto.
Conclusão: O Mirena® pode ser uma política pública eficaz que ajudaria a impulsionar o
cuidado com a saúde da mulher, e, consequentemente, reduzir os custos para o sistema de saúde
brasileiro.
Introduction: A survey conducted in 2021 showed that 62% of Brazilian women have had at least one unintended pregnancy. This numbers are considered alarming, since it is 14% above the world average and higher than the national average in 2012, which was 55%. It can be considered that, the absence of knowledge and access to contraceptive methods is the main cause of this problem. To reduce these numbers, it is necessary to expand the dissemination of information about contraception in SUS, ensure access to modern methods and train multidisciplinary teams for contraceptive counseling of patients. It is also important to encourage and train these professionals and enhance the participation of pharmacists in the process. The present study emphasizes the use of the levonorgestrel 52mg intrauterine delivery system (Mirena®) as a modern, safe and effective alternative for contraception. Increased access to modern contraceptive methods, such as Mirena®, can significantly contribute to the reduction of unintended pregnancy rates in Brazil. Objective: To evaluate the benefits of using the levonorgestrel 52mg Intrauterine Delivery System in the Brazilian Unified Health System (SUS). Methods: This is a systematic review of selected studies on the use of Mirena® in Brazil. A search was conducted in databases such as SciELO and Pubmed, using the combination of keywords: levonorgestrel intrauterine system and Brazil, in English and Portuguese. Five relevant publications were found and analyzed. Results and Discussions: The analyzed publications support the idea that Mirena® is very effective, both for controlling unintended pregnancy rates, treatment of idiopathic HMB (Heavy Menstrual Bleeding) and endometrial protection. Moreover, it has some advantages when compared to other treatments and methods, and its cost-effectiveness may be advantageous. On the other hand, it is necessary, in parallel, to strengthen the public health system and invest in researches about this theme. Conclusion: Mirena® may be an effective public policy that would help to improve women's health care, and consequently reduce costs to the Brazilian health care system.
Introduction: A survey conducted in 2021 showed that 62% of Brazilian women have had at least one unintended pregnancy. This numbers are considered alarming, since it is 14% above the world average and higher than the national average in 2012, which was 55%. It can be considered that, the absence of knowledge and access to contraceptive methods is the main cause of this problem. To reduce these numbers, it is necessary to expand the dissemination of information about contraception in SUS, ensure access to modern methods and train multidisciplinary teams for contraceptive counseling of patients. It is also important to encourage and train these professionals and enhance the participation of pharmacists in the process. The present study emphasizes the use of the levonorgestrel 52mg intrauterine delivery system (Mirena®) as a modern, safe and effective alternative for contraception. Increased access to modern contraceptive methods, such as Mirena®, can significantly contribute to the reduction of unintended pregnancy rates in Brazil. Objective: To evaluate the benefits of using the levonorgestrel 52mg Intrauterine Delivery System in the Brazilian Unified Health System (SUS). Methods: This is a systematic review of selected studies on the use of Mirena® in Brazil. A search was conducted in databases such as SciELO and Pubmed, using the combination of keywords: levonorgestrel intrauterine system and Brazil, in English and Portuguese. Five relevant publications were found and analyzed. Results and Discussions: The analyzed publications support the idea that Mirena® is very effective, both for controlling unintended pregnancy rates, treatment of idiopathic HMB (Heavy Menstrual Bleeding) and endometrial protection. Moreover, it has some advantages when compared to other treatments and methods, and its cost-effectiveness may be advantageous. On the other hand, it is necessary, in parallel, to strengthen the public health system and invest in researches about this theme. Conclusion: Mirena® may be an effective public policy that would help to improve women's health care, and consequently reduce costs to the Brazilian health care system.